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Abstract: Antibiotic resistance has been reported since the 1940s in both human and veterinary
medicine. Many years of monitoring milk samples in South Africa led to identification of a novel
maltose-negative Staphylococcus aureus (S. aureus) strain, which appears to be an emerging pathogen.
In this study, the susceptibility of this strain to antibiotics was evaluated over time, during diverse
seasons in various provinces and according to somatic cell count (SCC) categories. A data set of
271 maltose-negative S. aureus isolates, from milk samples of 117 dairy herds, was examined using the
disk diffusion method, between 2010 and 2017. This study also compared the susceptibility testing of
57 maltose-negative and 57 maltose-positive S. aureus isolated from 38 farms, from three provinces
using minimum inhibitory concentration (MIC). The MIC results for the maltose-negative S. aureus
isolates showed highest resistance to ampicillin (100%) and penicillin (47.4) and lowest resistance
(1.8%) to azithromycin, ciprofloxacin and erythromycin. The maltose-negative S. aureus isolates
showed overall significantly increased antibiotic resistance compared to the maltose-positive strains,
as well as multidrug resistance. Producers and veterinarians should consider probability of cure of
such organisms (seemingly non-chronic) when adapting management and treatment, preventing
unnecessary culling.
Keywords: antibiotic resistance; MIC; Staphylococcus aureus; mastitis; somatic cell count;
seasons; regions
1. Introduction
The genus Staphylococcus comprises various opportunistic pathogens of variable relevance
in veterinary medicine. The most clinically relevant staphylococci in veterinary medicine are the
coagulase-positive Staphylococcus aureus [1], members of the S. intermedius group [2], and the non-aureus
staphylococci [3]. A noted property of staphylococci is their ability to develop resistance to antibiotics
(for example by mutations). Methicillin resistance is of particular relevance because it is conferred
by a presence of the mecA gene, encoding for producing an altered penicillin-binding protein (PBP)
(PBP2a or PBP2′) with a low affinity for the beta-lactam antibiotics (penicillin, older cephalosporins
and carbapenems) [4]. Methicillin-resistant S. aureus (MRSA) is recognised as problematic in human
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medicine. It is identified among the organisms causing the most challenging infections in hospitalised
individuals and individuals in general [5].
In South Africa, S. aureus (maltose-positive) remains a challenge in udder health [6], even though
this was reported as no longer the main challenge to udder health in most countries [7]. Mastitis caused
by S. aureus remains a conundrum in South Africa because it is resistant to most antibiotics and
cannot be cured. A high proportion of cows are culled for this reason, with an important negative
economic impact on the dairy herd. The infected udder is considered the primary reservoir of S. aureus;
the organism is believed to be transmitted during milking. Despite this, a proportion of heifers already
infected with S. aureus enter the milking herd [8]. This suggests routes of transmission in addition to
the milking equipment and the milking parlour. An adequate comprehension of S. aureus reservoirs
and transmission is essential for the effective control of the organism in a herd. The expected treatment
resulting in the cure of S. aureus (maltose-positive) infection can be estimated by considering the
following factors; parity, the stage of lactation, the SCC level, the specific teat position on the udder
and the number of quarters infected and the duration of the required treatment [9].
The milk laboratory at the Faculty of Veterinary Science at the University of Pretoria provided an
extensive dairy cow udder monitoring programme in South Africa. Since 2005, an increasing number
of coagulase-positive, maltose-negative staphylococci was isolated, confirmed as maltose-negative
S. aureus by MALDI-TOF and 16S rRNA sequencing methods [10]. These organisms were first
identified from a dairy cow in a single South African dairy herd with an average individual somatic
cell count of less than 100,000 cell/mL of milk. Three years later, similar organisms were isolated
from numerous dairy herds in South Africa, although with effective susceptibility to antibiotics
assessed routinely, with a low SCC [11]. These organisms did not cause the same level of udder
damage than maltose-positive S. aureus and did not cause any chronic or repeat cases in South
Africa [11]. In more recent years (2016/2017/2018), individual coagulase-positive and maltose-negative
staphylococci indicated resistance (MRSA, cefoxitin disk), and an increase in SCC of infected udders
(> 400,000cells/mL milk) [11]. Inadequate informing concerning maltose-negative S. aureus from dairy
cows also exists. A study in the Netherlands also isolated a maltose-negative strain of S. aureus [12].
The strain established in the Netherlands [12] differed from that investigated in this study in South
Africa. In addition to the previous study [10], attempting to characterise this emerging pathogen,
a further evaluation was conducted from the resistance trends, evident in historic disk diffusion
susceptibility data, and more recent MIC data, the results of which are presented in this study.
The first and main objective of this study was to investigate the retrospective (disk diffusion)
antibiotic surveillance data of unique maltose-negative S. aureus ST 2992 in various provinces,
seasons and SCC categories over time. The second objective was to compare the MIC results of
the maltose-negative S. aureus, previously identified as an emerging pathogen [10], to those of
maltose-positive S. aureus.
2. Results
2.1. Retrospective Data—Disk Diffusion Method
The first part of this study comprised the retrospective data analysis (disk diffusion) conducted on
maltose-negative S. aureus, employing the latest CLSI breakpoints available during the study [13,14].
The eight antibiotics used in this retrospective study comprised the commonly used antibiotics available
as intramammary remedies in South Africa. According to the univariate analyses, the proportion
of resistance amongst the maltose-negative S. aureus isolates identified varied significantly per SCC
category for cloxacillin. The proportions of resistance differed significantly between seasons for
ampicillin, penicillin and cephalexin.
The trends of penicillin G, ampicillin, cephalexin, cephalonium and oxytetracycline resistance
peaked (at highest) in 2011, and for tylosin in 2013, then decreased over time (Figure 1a–f). In 2017,
a slight increase in antibiotic resistance to ampicillin, penicillin G and tylosin but not for cephalexin,
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was indicated (Figure 1a–c,f). For Figure 1a–f, the represented period was limited to 2012 to 2017 as
there were inadequate data for the previous years, resulting in exceptionally large confidence intervals.
The generalised linear mixed model (GLMM) results confirmed that time (years) was a significant
variable for antibiotic resistance of maltose-negative S. aureus to penicillin G, ampicillin, cephalonium,
oxytetracycline, cephalexin and tylosin. The association between the logit of resistance against tylosin
and year was nonlinear (Table 1). According to the GLMM analysis, the SCC category represents
the significant predictor for antibiotic resistance to cloxacillin (Table 1). The SCC category was
significant for the cephalonium resistance (Table 1). “Season” was a significant variable for penicillin
G, ampicillin and cephalexin. Spring was the season with the lowest level of resistance compared to
autumn and summer for penicillin G and ampicillin, whereas autumn was the season with the lowest
resistance level for cephalexin compared to summer. No effect of province on antibiotic resistance was
detected (Table 1).
Table 1. Summary variables on antibiotic resistance effects of GLMM for maltose-negative S. aureus,
according to the CLSI breakpoints used [13].
Antibiotics Year Season Province SCC Category
Tylosin Cubic effect (p < 0.001 forYear, Year2 and Year3) NS NS NS
Penicillin G p = 0.018
p = 0.05 [Autumn p = 0.03
& Summer p = 0.02] vs.
Spring (Lowest R)
NS NS
Ampicillin p = 0.008 N/A NS NS
Clindamycin N/A NS N/A N/A
Cefuroxime NS NS NS NS
Cephalonium
(2011–2017) p = 0.03 * NS NS
p = 0.027 [High SCC p = 0.007] vs.
Med SCC (Lowest R)
Cefoxitin
(2014–2017) NS NS NS NS
Oxytetracycline p < 0.001 NS NS NS
Cephalexin p = 0.017 p = 0.06 [p = 0.01 Summer]vs. Autumn (Lowest R) NS NS
Cloxacillin NS NS NS p = 0.022 [Low SCC p = 0.08] vs.High SCC (Lowest R)
* Almost significant p < 0.1, NS = Not Significant, R = Resistance, N/A = Not applicable.
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Table 2. The minimum inhibitory concentrations (MIC) 90 and MIC 50 for maltose-positive and 
maltose-negative S. aureus. 
Product 
% Resistance 
Maltose-
Positive 
S. aureus (n) 
% Resistance 
Maltose-
Negative 
S. aureus (n) 
MIC 90 MIC 50 Fisher’s 
Exact 
Test 
p-Value 
Maltose-
Positive S. 
aureus 
Maltose-
Negative S. 
aureus 
Maltose-
Positive S. 
aureus 
Maltose-
Negative 
S. aureus 
Amox/K Clav 3.5 (2/57) 21.1 (12/57) 1 2 0.5 0.5 0.008 ** 
Ampicillin 100 (57/57) 100 (57/57) 4 4 0.5 0.5  
Azithromycin 3.5 (2/57) 1.8 (1/57) 1 1 _ _  
Cefepime 1.8 (1/57) 22.8 (13/57) 4 4 _ _  
Cefotaxime 1.8 (1/57) 22.8 (13/57) 1 2 _ _ 
p < 0.001 
** 
Cefoxitin 1.8 (1/57) 0 (0/57) 4 4 _ _  
Cefuroxime 1.8 (1/57) 21.1 (12/57) 4 8 _ _ 0.002 ** 
Ciprofloxacin 7 (4/57) 1.8 (1/57) 1 0.5 0.5 _  
Clindamycin 5.3 (3/57) 24.6 (14/57) 0.3 _ _ 0.25 0.007 ** 
Daptomycin 0 (0/57) 17.5 (10/57) 0.5 _ _ 0.5 0.001 ** 
Ertapenem 1.8 (1/57) 15.8 (9/57) 0.5 0.5 _ 0.5 0.016 * 
Erythromycin 3.5 (2/57) 1.8 (1/57) 1 _ _ 1  
Fosfomycin 1.8 (1/57) 12.3 (7/57) 32 _ _ 32  
Fusidic Acid 0 (0/57) 10.5 (6/57) 2 _ _ 2 0.027 * 
Gentamicin 7 (4/57) 22.8 (13/57) 1 2 _ 1 0.033 * 
Imipe em 3.5 (2/57) 21.1 (12/57) 2 2 _ _  
Levofloxacin 0 (0/57) 0 (0/57) 1 1 _ _  
Linezolid 0 (0/57) 15.8 (9/57) 2 _ 1 2 0.003 * 
Meropenem 1.8 (1/57) 21.1 (12/57) 2 2 _ _  
Moxifloxacin 0 (0/57) 0 (0/57) 0.5 0.5 _ _  
Nitrofurantoin 0 (0/57) 8.8 (5/57) 64 64 _ _  
Oxacillin 1.8 (1/57) 21.1 (12/57) 0.3 _ 0.5 0.25 0.002 ** 
Penicillin 36.8 (21/57) 47.4 (27/57) _ _ 0.03 0.12  
Rifampin 0 (0/57) 5.3 (3/57) 0.5 0.5 _ _  
Synercid 5.3 (3/57) 19.3 (11/57) 1 _  1 0.043 * 
Teicoplanin 0 (0/57) 14 (8/57) 1 _ _ 1 0.006 ** 
Tetracycline 7 (4/57) 7 (4/57) 1 1 1 _  
Tobramycin 3.5 (2/57) 7 (4/57) 1 1 _ _  
Trimeth/Sulpha 0 (0/57) 0 (0/57) 1 1 _ _  
Vancomycin 0 (0/57) 31.6 (18/57) 2 _ 1 1  
Amox/K Clav = Amoxicillin Clavulanate; Trimeth/Sulpha = Trimethoprim/Sulphamethoxazole; n = 
number of isolates; * significant p < 0.05; ** significant p < 0.001 
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Figure 1. Trends of antibiotic resistance mean (proportion of isolates per year) of maltose-negative S. 
aureus (disk diffusion, retrospective data), according to CLSI [13,14]: (a) to ampicillin, (b) to penicillin 
G, (c) to cephalexin, (d) to cephalonium, (e) to oxytetracycline and (f) to tylosin. 
3. Discussion 
The breakpoints (CLSI) [13,14] are not just an indication of resistance, but they also consider 
concentrations at the udder level (i.e., its pharmacological resistance). In South Africa, a limited 
number of antibiotics are available as intramammary remedies, which consist mostly of ampicillin, 
cloxacillin or combinations thereof. The antibiotics with available breakpoints for mastitis specifically 
(ceftiofur, penicillin-novobiocin and pirlimycin), as indicated in the latest CLSI guidelines [13], are 
not available in the South African market. Other available CLSI veterinary breakpoints [13] were 
therefore used. For products on the Pos MIC 32 panel with no available veterinary breakpoints, the 
CLSI human breakpoints [14] were used, as explained and used in the publication which explains the 
development of veterinary antibiotic susceptibility guidelines over time [16]. 
This study indicated no significant differences (at a significance level of, p < 0.05) of antibiotic 
resistance amongst the provinces on the maltose-negative S. aureus, with a limited significant 
difference concerning seasons and SCC categories (Table 1). 
Figure 1. Trends of antibiotic resistance mean (proportion of isolates per year) of maltose-negative
S. aureus (disk diffusion, retrospective data), according to CLSI [13,14]: (a) to ampicillin, (b) to penicillin
, (c) to cephalexin, (d) to cephaloniu , (e) to oxytetracycline and (f) to tylosin.
2.2. Minimum Inhibitory Concentration (MIC) Analysis
Table 2 displays the antibiotics used in this study, from the Pos MIC 32 panel (Beckman
Coulter), indicating resistance to the isolates tested (Tables S1 and S2). The 57 maltose-positive
and the 57 maltose-negative S. aureus isolates indicated resistance to ampicillin. From the total of
114 isolates, 37 were resistant to more than one antibiotic; 30 were maltose-negative S. aureus and seven
maltose-positive S. aureus. A total of 25 multidrug-resistant (MDR) isolates (resistant to an antibiotic
from three or more antibiotic categories) were indicated [15], of which three were maltose-positive
and 22, maltose-negative S. aureus (Table S2). Multidrug resistance varied significantly between
maltose-positive and maltose-negative S. aureus (p < 0.001).
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Table 2. The minimum inhibitory concentrations (MIC) 90 and MIC 50 for maltose-positive and
maltose-negative S. aureus.
Product
% Resistance
Maltose-Positive
S. aureus (n)
% Resistance
Maltose-Negative
S. aureus (n)
MIC 90 MIC 50 Fisher’s Exact
Test
p-Value
Maltose-Positive
S. aureus
Maltose-Negative
S. aureus
Maltose-Positive
S. aureus
Maltose-Negative
S. aureus
Amox/K
Clav 3.5 (2/57) 21.1 (12/57) 1 2 0.5 0.5 0.008 **
Ampicillin 100 (57/57) 100 (57/57) 4 4 0.5 0.5
Azithromycin 3.5 (2/57) 1.8 (1/57) 1 1 _ _
Cefepime 1.8 (1/57) 22.8 (13/57) 4 4 _ _
Cefotaxime 1.8 (1/57) 22.8 (13/57) 1 2 _ _ p < 0.001 **
Cefoxitin 1.8 (1/57) 0 (0/57) 4 4 _ _
Cefuroxime 1.8 (1/57) 21.1 (12/57) 4 8 _ _ 0.002 **
Ciprofloxacin 7 (4/57) 1.8 (1/57) 1 0.5 0.5 _
Clindamycin 5.3 (3/57) 24.6 (14/57) 0.3 _ _ 0.25 0.007 **
Daptomycin 0 (0/57) 17.5 (10/57) 0.5 _ _ 0.5 0.001 **
Ertapenem 1.8 (1/57) 15.8 (9/57) 0.5 0.5 _ 0.5 0.016 *
Erythromycin 3.5 (2/57) 1.8 (1/57) 1 _ _ 1
Fosfomycin 1.8 (1/57) 12.3 (7/57) 32 _ _ 32
Fusidic
Acid 0 (0/57) 10.5 (6/57) 2 _ _ 2 0.027 *
Gentamicin 7 (4/57) 22.8 (13/57) 1 2 _ 1 0.033 *
Imipenem 3.5 (2/57) 21.1 (12/57) 2 2 _ _
Levofloxacin 0 (0/57) 0 (0/57) 1 1 _ _
Linezolid 0 (0/57) 15.8 (9/57) 2 _ 1 2 0.003 *
Meropenem 1.8 (1/57) 21.1 (12/57) 2 2 _ _
Moxifloxacin 0 (0/57) 0 (0/57) 0.5 0.5 _ _
Nitrofurantoin 0 (0/57) 8.8 (5/57) 64 64 _ _
Oxacillin 1.8 (1/57) 21.1 (12/57) 0.3 _ 0.5 0.25 0.002 **
Penicillin 36.8 (21/57) 47.4 (27/57) _ _ 0.03 0.12
Rifampin 0 (0/57) 5.3 (3/57) 0.5 0.5 _ _
Synercid 5.3 (3/57) 19.3 (11/57) 1 _ 1 0.043 *
Teicoplanin 0 (0/57) 14 (8/57) 1 _ _ 1 0.006 **
Tetracycline 7 (4/57) 7 (4/57) 1 1 1 _
Tobramycin 3.5 (2/57) 7 (4/57) 1 1 _ _
Trimeth/Sulpha 0 (0/57) 0 (0/57) 1 1 _ _
Vancomycin 0 (0/57) 31.6 (18/57) 2 _ 1 1
Amox/K Clav = Amoxicillin Clavulanate; Trimeth/Sulpha = Trimethoprim/Sulphamethoxazole; n = number of
isolates; * significant p < 0.05; ** significant p < 0.001.
3. Discussion
The breakpoints (CLSI) [13,14] are not just an indication of resistance, but they also consider
concentrations at the udder level (i.e., its pharmacological resistance). In South Africa, a limited
number of antibiotics are available as intramammary remedies, which consist mostly of ampicillin,
cloxacillin or combinations thereof. The antibiotics with available breakpoints for mastitis specifically
(ceftiofur, penicillin-novobiocin and pirlimycin), as indicated in the latest CLSI guidelines [13], are not
available in the South African market. Other available CLSI veterinary breakpoints [13] were therefore
used. For products on the Pos MIC 32 panel with no available veterinary breakpoints, the CLSI human
breakpoints [14] were used, as explained and used in the publication which explains the development
of veterinary antibiotic susceptibility guidelines over time [16].
This study indicated no significant differences (at a significance level of, p < 0.05) of antibiotic
resistance amongst the provinces on the maltose-negative S. aureus, with a limited significant difference
concerning seasons and SCC categories (Table 1).
According to the GLMM, the geographical origin (provinces) of the samples was not a significant
predictor of the resistance (Table 1). A total of 271 isolates were identified, with an unequal distribution
amongst the provinces. Despite the low number of isolates (<10) for six provinces, this indicated no
difference in the resistance amongst Kwa Zulu Natal, Eastern Cape and Western Cape (with 170, 56 and
27 isolates, respectively). This discrepancy forbids a statistical analysis to demonstrate differences
amongst all the provinces. The relationship of SCC to antibiotic resistance was similar to that of a
study in Finland [17], which also established that in some cases a higher SCC could correspond with
low antibiotic resistance and contrariwise. This could be attributable to the SCC being more of an
indicator of irritation and severity of the infection rather than an indicator of antibiotic resistance of
the organism. The study on maltose-positive S. aureus [18] indicated that the lowest prevalence of
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antibiotic resistance to most categories of antibiotics tested was present in KwaZulu-Natal during
spring, except for cephalosporins, holding the lowest levels of prevalence of bacterial resistance in
Gauteng during winter [18]. A possible reason for lower prevalence of antibiotic resistance of S. aureus
to cephalosporins during winter in Gauteng may be that the dry cold season has generally a lower
probable prevalence of intramammary infections that would require less treatment [18]. This would be
supported by the occurring higher average incidence of frost duration in Gauteng [19], which would
have suppressed insect vectors associated in mastitis pathogen transmission [20]. Reasons for these
variations are unclear. Antibiotic resistance could also occur from random genetic mutations and
subsequent natural selection of bacteria in order for them to survive [18].
Although great differences were identified in the numbers of herds and samples amongst the
provinces, these differences were considered in the model during the analysis.
At that time (2009) a specific strain of maltose-negative S. aureus ST 2992 was identified [10],
originating in and established mostly in KwaZulu-Natal, now established to be present in all provinces
of South Africa, although in small quantities. The antibiotic resistance trends over time of this
maltose-negative S. aureus (Figure 1a–f) agreed with those indicated for the same antibiotics with
non-aureus staphylococci [21], but in contrast to the trends indicated for the maltose-positive S. aureus
over time [22]. The maltose-positive S. aureus study indicated a general increase in resistance over
time except for identified well-managed herds (part of the pro-active udder health programme) [22],
indicating a decrease in resistance over time [22]. Other medical studies also showed a decrease
in antibiotic resistance through the change in bacterial population resulting from good biosecurity
measures [23]. In one medical study, a 9% year-on-year decrease in methicillin-resistant S. aureus
(MRSA) cases was reported [24]. These medical studies have illustrated how the resistance profiles of
bacteria can change under intensive care unit biosecurity programmes [23,24]. However, worldwide the
increase of antibiotic resistance and rapid increase of resistant bacteria has reached a crisis, where many
antibiotics which have transformed medicine and saved millions of lives are no longer effective
against even the simplest infections [25,26]. Such infections often result in an increased number of
hospitalisations, more treatment failures and the persistence of drug-resistant pathogens [25]. A recent
World Health Organization (WHO) health report has warned that resistance to antibiotics in general is
a “global” threat [27], and one that impacts on both human health care and the agricultural industry.
The MIC results (Table 2) confirmed the disk diffusion results (Table 1) for maltose-negative
S. aureus for the tested products.
Table 2 summarises the distribution of the assessed antibiotics MIC test results for the respective
maltose-positive and maltose-negative S. aureus isolates (Table S1). Twelve maltose-negative S. aureus
isolates were resistant to oxacillin, compared to one maltose-positive S. aureus. The same pattern
was observed for ertapenem; nine maltose-negative S. aureus isolates were resistant, compared to
one maltose-positive S. aureus. The MICs of most products in the Pos MIC 32 panel differed between
maltose-negative and maltose-positive S. aureus isolates (Table 2 and Table S1). The resistance rates of
the maltose-positive S. aureus obtained in this study corresponded appropriately to those reported in
additional studies [28].
The (MIC 50) represents the MIC value at which≥50% of the isolates in a test population are inhibited,
equivalent to the median MIC value. The (MIC 90) represents the MIC value at which >90% of the isolates
in the test population are inhibited [29]. The MIC breakpoints are the chosen concentrations [µg/mL] of an
antibiotic, defining whether a species of bacteria is described as susceptible or resistant to the antibiotic.
Certain antibiotics were susceptible for MIC 50 and MIC 90 for both the maltose-negative and the
maltose-positive S. aureus, except for MIC 90 of maltose-negative S. aureus (Table 2). The maltose-negative
S. aureus was significantly more resistant (p < 0.001) to the amoxicillin–clavulanic acid combination
(used in human medicine) and cefuroxime at MIC 90, and for clindamycin at MIC 50 (Table 2).
Maltose-positive S. aureus was significantly more resistant (p < 0.001) to oxacillin for MIC 90 and MIC 50
and to clindamycin for MIC 90 (Table 2). Infrequently established resistance patterns were established in
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18 of the 57 maltose-negative S. aureus isolates, resistant to vancomycin, and one maltose-positive and
12 maltose-negative S. aureus isolates were oxacillin resistant (Table S1) [30].
This study identified more multidrug-resistant maltose-negative S. aureus than maltose-positive
S. aureus isolates (p < 0.001) (Table S2). The same interpretation applied for isolates resistant to
two or more antibiotics of varying combinations. Several studies in animal and human medicine
identified multidrug-resistant and pan drug-resistant S. aureus isolates [31]. Most of these studies
were conducted on traditionally identified coagulase-positive, maltose-positive S. aureus. Although a
coagulase-positive, maltose-negativeS. aureus strain was subsequently isolated from bovine mastitis [12],
no antibiotic susceptibility profiles of this organism were present. MALDI-TOF MS and 16S r RNA
sequence analysis [10] identified the maltose-negative S. aureus ST 2992 isolated from milk samples in
South Africa.
Human nasal S. aureus colonisation was previously reported as a pig farming risk factor [32]; S. aureus
strains from pig farmers were present in pigs and not in non-farmers [32,33]. Considering pig research,
it is possible that in the similar transmission of some strains of this resistant S. aureus (predominantly
maltose-negative strains), isolated from dairy cattle in South Africa, could be from people. Previous
studies in KwaZulu-Natal [34] identified Anthroponosis of S. aureus in South Africa, with one of the strains
as the same maltose-negative S. aureus strain. Antibiotics approved for human use are a resource of unique
antibiotics that should be kept for use in humans. Antibiotics approved for animal use only, such as the
ionophores, should not create a risk to human health [35,36]. These maltose-negative S. aureus strains
have different antibiotic resistance trends and antibiotic resistance severity compared to the traditionally
identified maltose-positive S. aureus (Table 2). These two organisms react conversely in practice and
should, therefore, be treated differently in practice [10].
This research identified 21 isolates of maltose-negative S. aureus with uncommon resistance
profiles to antibiotics used in human medicine (such as the carbapenems; imipenem (n = 12) and
ertapenem (n = 9)) [37]. These are antibiotics not used in animal medicine. Anthroponosis is a strong
possibility because these isolates were present on the skin of humans who were in close contact with
dairy cattle. This would be similar to the findings of the studies with the dogs in Brazil [38], pigs in
Germany [32] and the Netherlands [39], respectively. Further studies are needed to explore the origin
of such resistant isolates of maltose-negative S. aureus. Future work is also necessary to determine the
resistance genes present in resistant maltose-negative S. aureus strains.
A similar study in dairy cattle in Tennessee also established a variation of prevalence of antibiotic
resistance of S. aureus, with an increasing trend in tetracycline resistance [40]. These conclusions
followed the report identifying the predominant antibiotic groups used in animal health in South Africa
from 2014 to 2015, as the growth promoters (animal use only antibiotics) (62%) followed by tetracyclines
(17%) and macrolides (11%) [41]. This study indicated five isolates resistant to tetracyclines, and ten
isolates resistant to macrolides. Only one of each isolate was maltose-positive, whereas the rest were
maltose-negative S. aureus.
Antibiotics used in South Africa in 2015 were identified as 21,149 standard units per 1000 human
population (IMS Health 2015) (Note: 1 standard unit is equivalent to one tablet, or injection); this was
significantly higher than in most other countries globally. Broad-spectrum penicillin use in humans in
South Africa was 1.3 to 3.3 times higher than in other countries and 0.8 times higher than in the United
Kingdom or the USA [41]. It is undecided if the high number of maltose-negative S. aureus isolates
resistant to penicillin and ampicillin might solely be attributed to the high antibiotic usage.
The antibiotic resistance trends (Figure 1a–f) and profiles (Table 2), allow for informed treatment
decisions without pausing for specific antibiotic sensitivity test results where animal-specific breakpoints
are used [16]. The antibiotic sensitivity test results of (disk diffusion or MIC), are an indication in vitro
that the particular organism is liable to be destroyed by a particular antibiotic. In the udder, the situation
may be different because the site of the infection may be difficult to reach through small arteries and
lactiferous ducts, attributable to udder pharmacokinetics (very few products are successful in a water
and fat environment). As a result, mastitis treatment success is not exceedingly high (27%) [42] and can
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lead to antibiotic resistance development by mastitis-causing organisms. Although treatment against
S. aureus is generally more successful in the dry period, it is still not ideal [43]. Therefore for mastitis
control, the focus should be on the proactive udder health programme prevention and monitoring [44],
rather than on treatment alone.
4. Materials and Methods
The milk laboratory of the Faculty of Veterinary Science (University of Pretoria, Pretoria, Gauteng,
South Africa) received samples from most commercial dairies in South Africa since 1999, as part of the
proactive udder health programme (routine testing of microbiology and cytology, every two to three
months) [22]. This sampling entailed mostly routine whole herd investigations, which included all
the lactating animals in the herd and detecting all intramammary infections, clinical and subclinical.
Bacteriological analyses are conducted routinely on these samples. Two-hundred-and-seventy-one
maltose-negative S. aureus isolates were identified from 117 dairy herds from the samples received
from 2000 dairy farms between 2009 and 2017 [45], with 4, 8, 4, 21, 18, 44, 65, 91 and 16 isolates, for the
years 2009, 2010, 2011, 2012, 2013, 2014, 2015, 2016 and 2017, respectively. The milking intervals for
these dairy herds were either 12 or 8 hourly, depending on the number of milkings per day. Each herd
was approached on an individual basis. The lactating cows in the 117 herds in this study varied from
30 (smallest herd) to 1700 cows (largest herd) [45]. The study population included mainly Holstein
Friesian, Holstein crossbreeds, crossbreeds and Jersey dairy cows. Cows differed in age, parity, days in
milk and milk yield. These herds were located in the nine provinces of South Africa, with unbalanced
numbers of organisms among the provinces, indicating, Gauteng (n = 8), KwaZulu-Natal (n = 170),
Free State (n = 4), Eastern Cape (n = 56), Western Cape (n = 27), Northern Cape (n = 1), North West
(n = 1), Limpopo (North) (n = 1) and Mpumalanga (n = 3). The maltose-negative S. aureus isolated per
farm varied from one to nineteen.
The single foremilk milk samples were collected in an aseptic manner according to a standard
operating procedure [46]. Sampling was performed in the parlour prior to milking, at the routine
milking intervals of each farm, as described above. Milk samples were taken by professional samplers
or milkers trained according to a standard operating procedure [46]. Prior to sampling, the first milk
was stripped from all quarters and the teat ends were carefully cleaned and disinfected with methylated
alcohol. Approximately 10 mL of milk was collected in an aseptic manner into sterile marked
sample tubes and kept refrigerated until shipment. In the case of composite milk samples, the same
procedure was followed, but approximately equal volumes of milk from each of the four quarters
were collected in one sample tube [46]. Milk samples were submitted by producers, veterinarians
and field workers within 48 h after sample collection on ice to the laboratory [22]. Temperatures and
conditions such as sample tube cleanliness and appearance were noted on arrival at the laboratory,
and samples that were spoiled or of doubtful quality were not processed. Samples were plated out
at the laboratory on the day of their arrival. Most of these dairy producers send composite milk
samples to the Milk Laboratory, Faculty of Veterinary Science, University of Pretoria, for testing
(microbiology and cytology) on a routine basis, as part of a proactive udder health management
programme. In the case of mastitis outbreaks or clinical mastitis cases, quarter milk samples are
used as a follow-up test method [22]. These isolates were collected and cultured according to the
method recommended by the National Mastitis Council [46]. The laboratory investigation took place
in the milk laboratory at Department of Production Animal Studies, Faculty of Veterinary Science,
University of Pretoria. All milk samples were visually inspected and were then cultured on bovine
blood tryptose agar (BTA) (Columbia Blood Agar Base, CM331 from Oxoid, plus 5% defibrinated
bovine blood) and were incubated at 37 ± 1 ◦C for 24 to 48 h [46]. All samples in the current data
set were diagnosed by using one or more colonies in cases where S. aureus was suspected and two
or more in all other cases. Only pure cultures were used. Colonies were initially identified based
on colony morphology, haemolysis and potassium hydroxide (KOH) test results [47]. The catalase
reaction was used to differentiate between Gram-positive staphylococci and streptococci. Staphylase™,
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a coagulase test (Oxoid, supplied by Quantum Biotechnologies (Pty) Ltd., Ferndale, South Africa),
was used to distinguish between coagulase-positive and coagulase-negative staphylococci. Maltose
agar plates (Merck NT Laboratory Supplies, Halfway House, South Africa) were used for further
identification of staphylococci. A positive maltose agar reaction confirmed S. aureus; a negative maltose
reaction confirmed an organism potentially from the S. intermedius group [30,41], on initial phenotypic
identification [10]. These organisms were identified using the MALDI-TOF and 16S sequencing.
Both these methods confirmed a maltose-negative strain of S. aureus [10]. Further multi-locus sequence
typing (MLST) and analysis of the MalA and MalR genes, revealed maltose-negative S. aureus ST
2992 with an abnormal stop codon on the MalA gene (GenBank accession number, MN531305) [10].
Microbiological and cytological examinations were performed on all milk samples [46].
Somatic cell counts were counted by fluoro-opto-electronics, using a Fossomatic 5000 and
Fossomatic FC (Rhine Ruhr). Isolates to be tested for routine antibiotic susceptibility were selected
from milk samples with a somatic cell count (SCC) (Fossomatic 5000 and Fossomatic FC, Rhine Ruhr)
of over 400,000 cells/mL [8,21], when applicable, to include subclinical mastitis cases. This was the
general rule for routine antibiotic susceptibility testing. When a maltose-negative S. aureus was isolated
from a herd, antibiotic sensitivity testing was conducted on that organism, regardless of SCC [10].
The Kirby–Bauer disk diffusion method [48] was used to determine the antibiotic susceptibility of the
routine diagnostic samples for the retrospective data analysis. At least four to five well-isolated colonies of
the same morphological type from an agar plate were selected for the Kirby–Bauer disk diffusion test [48].
The results were based on the inhibition zones diameter and were classified as sensitive, intermediate or
resistant under the latest clinical breakpoints available during the study, CLSI [13,14].
Antibiotic susceptibility was tested against nine intramammary antibiotics (in lactation and dry
cow therapy) available in South Africa. These were the penicillin (ampicillin 10 µg, cloxacillin 5 µg,
penicillin G 10 IU), cephalosporins (cephalexin 30 µg, cefuroxime 30 µg, cefoxitin 30 µg), lincosamides
(clindamycin 10 µg), tetracyclines (oxytetracycline 30 µg) and macrolides (tylosin 30 µg).
Minimum inhibitory concentrations tests were conducted on 57 coagulase-positive,
maltose-negative S. aureus isolates (2012–2013 n = 15; 2018–2019 n = 42) and 57 maltose-positive
S. aureus isolates (2012–2014 n = 11; 2017–2018 n = 46), isolated from 38 dairy herds mainly from
KwaZulu-Natal and the Eastern Cape, with a few samples from the Western Cape, Gauteng and
Mpumalanga. The 57 maltose-negative S. aureus isolates were the total number of these isolates collected
during the mentioned periods. For the maltose-positive S. aureus isolates, the same number (n = 57) of
isolates from the same farms, with similar corresponding SCC ranges and from similar periods to those
of the maltose-negative S. aureus samples were selected. The selected antibiotic agents were based
upon the availability of commercial intramammary infusion products or as representatives of their
respective antibiotic classes, such as ampicillin, oxacillin, erythromycin, penicillin and tetracycline.
The MIC was determined by employing the automated broth microdilution method (Pos MIC 32
panels and Microscan 40 Walkaway system, Beckman Coulter, Brea, CA, USA). The antibiotics and
concentrations used for the MIC testing were as per the specifications on the package insert of the
commercially available PM 32 panel (Table 2). The results were evaluated according to CLSI [13,14].
Staphylococcus aureus ATCC 25923 and S. pseudintermedius ATCC 49444 functioned as reference strains
for quality control purposes. The MIC data analysis used the LabPro software of the Microscan
40 Walkaway system (Beckman Coulter, Brea, CA, USA) to determine the MIC 90; the MIC 50 was
calculated manually.
To analyse various factors that could affect the resistance of the isolates, a two-step approach was
used. Univariable analyses were first applied to explore the potential effects of these factors. Univariate
multivariable analyses [49] were then used to confirm these effects and to explore interactions.
The Chi-square test was used to verify the existence of any effect of season or SCC category on the
response variable, including the resistance to the various antibiotics. The used SCC categories were low
(< 150 × 103 cells per ml milk), medium (150 × 103 to 400 × 103 cells per ml milk), and high (> 400 × 103
cells per ml milk). The seasons were defined as spring (September to November), summer (December
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to February), autumn (March to May) and winter (June to August). The Fisher exact test was applied
to all nine provinces, testing this geographical effect attributable to the small numbers of isolates for six
of the provinces.
These Chi-square and Fisher tests also allowed classification of the categories of each variable
to introduce the variable with the lowest level of resistance as the reference category in the
following generalised mixed model (GLMM) analysis. Generalised linear mixed models are models
considering non-independence amongst clustered observations. The random variable defines the
clusters. As generalised models, they allow a nonlinear relationship between the dependent variable
(variable to be explained) and the model parameters [50]. In the univariate multivariable GLMM [40],
the drug-specific antibiotic resistance of all S. aureus isolates was used as the dependent variable.
As it is a binomial variable a logit link function was used. The herd was introduced as the random
variable. Then, season, province and SCC category were introduced as different categorical independent
variables (model parameters). The year was added as a numeric independent variable. The quadratic
and cubic effect of year was tested for each antibiotic, which indicated an effect of the year.
Under the “goal of parsimony”, a stepwise approach based on the smallest Akaike Information
Criterion was used to select the worthiest model [51]. The likelihood ratio test was applied to test
the significance of the retained fixed effects. P-values lower than 0.05 were considered as statistically
significant; p-values between 0.1 and 0.05 were considered as almost significant. The analysis was
conducted separately for each antibiotic, employing the R software © version 3.3.3 “lme4” and “afex”.
The Fisher’s exact test was conducted to compare the resistance level of maltose-negative and
maltose-positive S. aureus for each antibiotic and multidrug resistance.
The study presents a retrospective analysis approved by the University of Pretoria Ethics
Committee (reference number V062/14). The laboratory supplying the data provided a written consent
from owners for data to be used for research purposes, approved by the ethics committee.
5. Conclusions
The antibiotic resistance inclinations for ampicillin, cephalexin, cephalonium, cloxacillin,
oxytetracycline and penicillin G peaked (at highest) in 2011 and for tylosin in 2013, subsequently
decreasing. These antibiotic resistance trends over time revealed a closer comparison with the analysis
of similar data for non-aureus staphylococci than for the maltose-positive S. aureus. Antibiotic resistance
trends over time also differed between maltose-negative and maltose-positive S. aureus. Antibiotic
resistance of maltose-negative S. aureus indicated no significant differences amongst provinces,
with limited differences amongst seasons for ampicillin, penicillin G and cephalexin. For cloxacillin
and cephalonium specifically, high SCC corresponded with low antibiotic resistance, significantly
different from low SCC to correspond with a high antibiotic resistance cephalonium. The MIC
antibiotic resistance results for maltose-negative S. aureus confirmed the disk diffusion method results.
This showed that the Kirby–Bauer method, in addition to being a relatively quick and cost-effective
method, is also accurate enough for routine veterinary diagnostics for antibiotic sensitivity testing
in dairy cows. The results of the MIC method also indicated more resistance for maltose-negative
than for the maltose-positive S. aureus isolates to most of the antibiotics used. The MIC breakpoints
were susceptible at MIC 50 and MIC 90 for maltose-negative and maltose-positive S. aureus, except for
maltose-negative S. aureus at MIC 90. These findings also showed resistance of the maltose-negative
strain isolated from milk samples to antibiotics that are only used in human medicine, which implies
a possible anthroponosis (transfer from humans to animals) and requires further studies under the
“one health” approach. This study also highlighted the differences in antibiotic resistance profiles
between the maltose-positive and maltose-negative S. aureus. This is useful information for both
producers and veterinarians, in order to adapt different management and treatment protocols for
this maltose-negative S. aureus which seems not to be a chronic intra-mammary infection, preventing
unnecessary culling.
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This highlights the importance of individual organisms in antimicrobial resistance which is shown
by the higher antimicrobial resistance of maltose-negative S. aureus ST 2992 compared to that of
maltose-positive S. aureus, as well as multidrug resistance. The results of this surveillance study and
the availability of antibiotic resistance profiles for the maltose-negative S. aureus will allow for informed
decisions to be made on treatment and management of this emerging pathogen in practice.
Supplementary Materials: The following are available online at http://www.mdpi.com/2079-6382/9/9/616/s1,
Table S1: Distribution of minimum inhibitory concentrations (MIC) cumulative percentage for maltose-positive
and maltose-negative S. aureus, Table S2: Minimum inhibitory concentration (MIC) results of maltose-positive and
maltose-negative S. aureus resistant to more than one antibiotic.
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